eligibility_summary
Inclusion: histologically confirmed relapsed/refractory DLBCL, ECOG 0-2, adequate marrow, hepatic, renal function, 2+ prior systemic therapies (phase 2: 2-4) including anti-CD20, not candidates for, or unwilling/unable to receive, HD chemo/ASCT and/or CAR-T. Exclusion: prior anti-CD47, glofitamab, or anti-CD20xCD3, refractory to obinutuzumab monotherapy, prior allo-SCT or auto-SCT within 12 wks, high-grade B-cell lymphoma, active infection.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b/2 trial in relapsed/refractory DLBCL tests: 1) Maplirpacept (PF-07901801): anti‑CD47 biologic (receptor‑fusion–type) that blocks the CD47–SIRPα “don’t‑eat‑me” checkpoint to enhance macrophage phagocytosis of tumor cells. 2) Glofitamab (Columvi): CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that redirects CD3+ T cells to kill CD20+ B‑cell lymphoma. Obinutuzumab (Gazyva), a type II anti‑CD20 monoclonal antibody, is given once as a priming dose to deplete B cells and mitigate CRS before step‑up glofitamab. Targets/pathways: CD47 on lymphoma cells/SIRPα on macrophages, CD20 on malignant B cells, CD3 on T cells—combining macrophage phagocytosis with T‑cell cytotoxicity.